Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: A randomized crossover study (the MICRO study)-Reference-Cited by-同舟云学术

Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: A randomized crossover study (the MICRO study)

Published:2016-06-06 Issue:4 Volume:36 Page:1097-1103
ISSN:0733-2467
Container-title:Neurourology and Urodynamics
language:en
Short-container-title:Neurourol. Urodynam.

Author:

Torimoto Kazumasa¹,Matsushita Chie²³,Yamada Atsushi⁴,Goto Daisuke⁴,Matsumoto Yoshihiro⁵,Hosokawa Yukinari³,Miyake Makito¹,Aoki Katsuya¹,Hirayama Akihide⁶,Tanaka Nobumichi¹,Fujimoto Kiyohide¹

Affiliation:

1. Nara Medical University; Nara Japan

2. Saiseikai-Chuwa Hospital; Nara Japan

3. Tane General Hospital; Osaka Japan

4. Hirao Hospital; Nara Japan

5. Nara Prefecture General Medical Center; Nara Japan

6. Nara Hospital Kinki University Faculty of Medicine; Nara Japan

Funder

Astellas Pharma

Publisher

Wiley

Subject

Urology,Neurology (clinical)

Reference29 articles.

1. Prevalence and burden of overactive bladder in the United States;Stewart;World J Urol,2003

2. Epidemiologic survey of lower urinary tract symptoms in Japan;Homma;Urology,2006

3. MG Lucas DB Berghmans LC Bosch JLHR 2015 http://www.uroweb.org/guidelines/online-guidelines/

4. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline;Gormley;J Urol,2012

5. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder;Chapple;Eur Urol,2013

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mirabegron 50 mg once daily, long-term treatment maximizes benefit in middle-aged and older people with overactive bladder syndrome: a systematic review and meta-analysis of nine phase II/III, randomized, double-blind, parallel-design, placebo-controlled, multicenter, and multinational trials;Frontiers in Surgery;2024-08-26

2. Open-label, randomized, post-authorization study of mirabegron in Chinese participants with overactive bladder;Asian Journal of Urology;2024-07

3. Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial;World Journal of Urology;2024-03-02

4. What Are the Short-term Benefits and Potential Harms of Therapeutic Modalities for the Management of Overactive Bladder Syndrome in Women? A Review of Evidence Under the Auspices of the European Association of Urology, Female Non-neurogenic Lower Urinary Tract Symptoms Guidelines Panel;European Urology;2023-09

5. Efficacy of vibegron in patients with overactive bladder: Multicenter prospective study of real‐world clinical practice in Japan, SCCOP study 19‐01;LUTS: Lower Urinary Tract Symptoms;2021-10-28